Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Breast 3Thoracic 2Genitourinary 2CNS 2Sarcoma 1Dermatologic 1

Conditions

Ovarian Neoplasms 3Prostatic Neoplasms 1Peripheral Nervous System Diseases 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 136pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Drug Therapy 29Letrozole 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23Albumin-Bound Paclitaxel 23durvalumab 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20camrelizumab 20Specimen Handling 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × sagopilone × Gynecologic × Clear all
NCT00325351 2021-04-08

ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer

Bayer

Phase 2 Completed
45 enrolled
Gynecologic

Ovarian Neoplasms

NCT00246688 2015-12-31

Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer

Bayer

Phase 2 Completed
63 enrolled
Gynecologic

Ovarian Neoplasms

NCT00751205 2014-10-28

Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)

Bayer

Phase 2 Completed
150 enrolled
GenitourinaryGynecologic

Ovarian Neoplasms, Peripheral Nervous System Diseases, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡